Developer docs
API playgroundTry for free, no card

Search company profiles

Iterum Therapeutics

Full company profile

uuid0002mei

Namestring
Iterum Therapeutics
Legal namestring
Iterum Therapeutics plc
Websiteurl
iterumtx.com
Company typeenum
Public
Founded yearint
2015
Descriptiontext

Iterum Therapeutics plc was a clinical-stage and, briefly, commercial-stage pharmaceutical company incorporated in Ireland in 2015 and listed on NASDAQ (ticker ITRM) from May 2018 until its April 2026 delisting. The company developed sulopenem, a novel penem-class anti-infective, culminating in FDA approval of ORLYNVAH (sulopenem etzadroxil and probenecid) in October 2024 for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited or no alternative oral antibacterial options. ORLYNVAH was the first and only oral penem antibiotic approved in the United States and the first new branded product for uUTIs in over 25 years. The underlying technology combines sulopenem etzadroxil with probenecid in a proprietary bilayer tablet designed to deliver potent activity against multidrug-resistant Enterobacterales, including ESBL- and AmpC-producing organisms. An IV formulation of sulopenem and a 510(k)-cleared sulopenem susceptibility test disc (manufactured by Liofilchem) rounded out the technology portfolio.

Iterum generated revenue through direct U.S. sales of ORLYNVAH following its August 2025 commercial launch, with an initial Q3 2025 net product revenue of $0.4 million and 2026 guidance of $5-15 million. The company deployed an outsourced go-to-market model, engaging EVERSANA Life Science Services for sales and commercial operations, McKesson and Cencora for specialty distribution, ACS Dobfar for manufacturing, and rebate agreements with the top three Medicare Part D PBMs providing access to roughly 60+ million insured lives. Target customers were prescribers (infectious disease physicians and community prescribers across seven launch states) treating adult women with resistant uUTIs, with a $25 copay savings program supporting patient access.

Despite regulatory approvals and broad payer coverage, Iterum failed to scale commercial revenue quickly enough to support operations. Following a $5 million registered direct offering in April 2025, a deferral of a $20 million Pfizer milestone obligation to October 2029, and continued cash burn against $11 million in cash as of September 30, 2025, the company filed a winding-up petition in the Irish High Court on March 27, 2026. Joint Provisional Liquidators from Teneo Restructuring were appointed, shares were suspended and delisted from Nasdaq on April 1, 2026, and the company announced plans to cease operations and withdraw ORLYNVAH from the U.S. market.

Short descriptiontext

Iterum Therapeutics plc was a clinical-stage pharmaceutical company that developed and commercialized ORLYNVAH, the first FDA-approved oral penem antibiotic for uncomplicated urinary tract infections in adult women with resistant infections. The Irish-domiciled, NASDAQ-listed company filed for winding up in March 2026.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oral antibiotics, anti-infective therapeutics, penem antibiotics, urinary tract infection treatment, multi-drug resistant pathogens
Industry1 code
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Anti-Infective Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1ORLYNVAH Product Sales
TypeOne Time License
Description

Iterum generates revenue through direct sales of its FDA-approved antibiotic ORLYNVAH (oral sulopenem) for the treatment of uncomplicated urinary tract infections. The product launched commercially in August 2025 with initial Q3 2025 revenue of $0.4 million. The company projects 2026 net product sales between $5 million and $15 million depending on uptake and payer coverage.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1Patient copay program
ModelOtherBilling cadenceOne time
Notes

Eligible patients can obtain ORLYNVAH for as little as $25 through the copay savings program.

ir.iterumtx.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1ORLYNVAH
Description

Novel oral penem antibiotic (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs). The first and only oral penem antibiotic approved in the U.S.

globenewswire.com
Core offering1 text field

Iterum Therapeutics develops and commercializes ORLYNVAH (sulopenem etzadroxil and probenecid), a novel oral penem antibiotic bilayer tablet approved by the FDA for treating uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options. The company also holds patents and development assets around sulopenem, including IV formulations and a susceptibility test disc for laboratory use.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 57% of initial uncomplicated UTI infections were resistant to at least one antibiotic class; 13% were resistant to three or more
+2 more records
Product overview1 text field

Iterum Therapeutics is a clinical-stage pharmaceutical company that received FDA approval for its single commercial product, ORLYNVAH (sulopenem etzadroxil and probenecid), an oral penem antibiotic. The company also developed an IV formulation of sulopenem, though it remains unapproved. Both oral and IV formulations received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA in seven indications. The company commercialized ORLYNVAH through partnerships with EVERSANA for commercialization services, McKesson and Cencora for specialty distribution, and ACS Dobfar for manufacturing. The company filed for winding up in March 2026 and is in the process of dissolution.

Product and service2 records
1ORLYNVAH (sulopenem etzadroxil and probenecid)
CategoryAnti-infective pharmaceutical (oral antibiotic)
Description

Novel oral penem antibiotic combining sulopenem etzadroxil with probenecid in a bilayer tablet, FDA-approved (October 2024) for treating uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options, with potent activity against ESBL- and AmpC-producing Enterobacterales.

2Sulopenem Antimicrobial Susceptibility Test Disc (2 µg)
Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeOthersAnnounced on2026-03-27
Description

Appointed as Joint Provisional Liquidators to Iterum Therapeutics plc and Iterum Therapeutics International Limited following High Court order in Ireland. Damien Murran and Jennifer McMahon overseeing company wind-down and dissolution process.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2025-07-01
Description

Commercial Manufacturing and Supply Agreement for the manufacture and supply of ORLYNVAH bilayer tablets for commercial supply purposes.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-01
Description

Product Commercialization Agreement for commercialization of ORLYNVAH in the U.S. EVERSANA provides sales and commercial operations services, marketing, logistics, channel management, regulatory, medical affairs and other services related to commercialization of ORLYNVAH in the United States.

Strategic tierCoreTypeOthers
Description

Licensor of sulopenem technology with license agreement requiring royalty payments. In May 2025, Pfizer agreed to extend the deferral term for payment of the $20.0 million regulatory milestone payment until October 25, 2029.

5McKesson
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Specialty pharmacy distributor for ORLYNVAH allowing certain physicians to procure the product directly through McKesson specialty distribution channel.

globenewswire.com
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Specialty pharmacy distributor for ORLYNVAH allowing certain physicians to procure the product directly through Cencora specialty distribution channel.

7Top three Medicare Part D Pharmacy Benefit Managers
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Rebate agreements signed with top three Medicare Part D PBMs providing formulary coverage for ORLYNVAH. Initial agreements covered over 3.5 million lives, expanding to 10+ million lives with Medicare Advantage and Medicare Prescription Drug formularies.

investing.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Spero is the closest direct competitor, developing oral antibiotics (including tebipenem HBr) for complicated uUTIs caused by resistant pathogens — the same anti-infective / AMR niche as ORLYNVAH.

TypeBroad incumbent
Description

GSK received FDA approval for gepotidacin (Blujepa) for uUTIs in 2025, directly competing with ORLYNVAH in the resistant-uUTI space while operating across a much broader infectious disease and vaccines portfolio.

TypeDirect peer
Description

Melinta is a focused anti-infectives company (Baxdela, Orbactiv, Kimyrsa, Minocin) with hospital-channel infrastructure, comparable in size and therapeutic focus to Iterum at the point of ORLYNVAH's launch.

TypeDirect peer
Description

Tetraphase developed eravacycline (Xerava) for complicated intra-abdominal infections — a similarly differentiated, smaller-player anti-infective against MDR gram-negatives, now operating under Innoviva.

TypeDirect peer
Description

Paratek developed and commercialized Nuzyra (omadacycline), a differentiated antibiotic for community-acquired bacterial pneumonia and acute skin infections, mirroring Iterum's small-cap anti-infective commercial model.

TypeBroad incumbent
Description

Shionogi developed Fetroja/cefiderocol for MDR gram-negative infections, the closest large-pharma analog to sulopenem's spectrum; comparable in mechanism intent (siderophore/β-lactam strategy vs. penem strategy) and resistant-pathogen positioning.

TypeEmerging player
Description

VenatoRx is developing cefepime-taniborbactam for MDR gram-negative infections (acquired by GARDP for global rights), directly comparable as a small-cap anti-infective R&D story targeting the same AMR unmet need.

TypeOthers
Description

Pfizer is the licensor of the sulopenem technology and a broader anti-infective incumbent (with established hospital antibiotics), making it the most operationally entangled peer via the deferred $20M milestone and ongoing royalty relationship.

TypeBroad incumbent
Description

Merck markets Recarbrio and Zerbaxa for MDR gram-negative infections, providing a comparable large-cap commercial benchmark for what scaled uptake of a hospital/community β-lactam-based franchise looks like in the U.S.

10Nabriva Therapeutics
TypeDirect peer
Description

Nabriva developed and commercialized lefamulin (Xenleta), a first-in-class pleuromutilin antibiotic for community-acquired bacterial pneumonia — a closely analogous small-cap anti-infective launch with similar commercial-execution challenges.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Iterum Therapeutics

Anti-Infective Pharmaceuticalsiterumtx.com

Iterum Therapeutics plc was a clinical-stage pharmaceutical company that developed and commercialized ORLYNVAH, the first FDA-approved oral penem antibiotic for uncomplicated urinary tract infections in adult women with resistant infections. The Irish-domiciled, NASDAQ-listed company filed for winding up in March 2026.

What Iterum Therapeutics does

Iterum Therapeutics plc was a clinical-stage and, briefly, commercial-stage pharmaceutical company incorporated in Ireland in 2015 and listed on NASDAQ (ticker ITRM) from May 2018 until its April 2026 delisting. The company developed sulopenem, a novel penem-class anti-infective, culminating in FDA approval of ORLYNVAH (sulopenem etzadroxil and probenecid) in October 2024 for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited or no alternative oral antibacterial options. ORLYNVAH was the first and only oral penem antibiotic approved in the United States and the first new branded product for uUTIs in over 25 years. The underlying technology combines sulopenem etzadroxil with probenecid in a proprietary bilayer tablet designed to deliver potent activity against multidrug-resistant Enterobacterales, including ESBL- and AmpC-producing organisms. An IV formulation of sulopenem and a 510(k)-cleared sulopenem susceptibility test disc (manufactured by Liofilchem) rounded out the technology portfolio.

Iterum generated revenue through direct U.S. sales of ORLYNVAH following its August 2025 commercial launch, with an initial Q3 2025 net product revenue of $0.4 million and 2026 guidance of $5-15 million. The company deployed an outsourced go-to-market model, engaging EVERSANA Life Science Services for sales and commercial operations, McKesson and Cencora for specialty distribution, ACS Dobfar for manufacturing, and rebate agreements with the top three Medicare Part D PBMs providing access to roughly 60+ million insured lives. Target customers were prescribers (infectious disease physicians and community prescribers across seven launch states) treating adult women with resistant uUTIs, with a $25 copay savings program supporting patient access.

Despite regulatory approvals and broad payer coverage, Iterum failed to scale commercial revenue quickly enough to support operations. Following a $5 million registered direct offering in April 2025, a deferral of a $20 million Pfizer milestone obligation to October 2029, and continued cash burn against $11 million in cash as of September 30, 2025, the company filed a winding-up petition in the Irish High Court on March 27, 2026. Joint Provisional Liquidators from Teneo Restructuring were appointed, shares were suspended and delisted from Nasdaq on April 1, 2026, and the company announced plans to cease operations and withdraw ORLYNVAH from the U.S. market.

Iterum Therapeutics firmographics

Firmographics
Name
Iterum Therapeutics
Legal name
Iterum Therapeutics plc
Website
https://iterumtx.com
Company type
Public
Founded year
2015
Operating status
Closed
Headcount range
11–50 employees
Short description
Iterum Therapeutics plc was a clinical-stage pharmaceutical company that developed and commercialized ORLYNVAH, the first FDA-approved oral penem antibiotic for uncomplicated urinary tract infections in adult women with resistant infections. The Irish-domiciled, NASDAQ-listed company filed for winding up in March 2026.
Ownership category
akta.pro rank

Iterum Therapeutics industry classification

Industry
Product category
Anti-Infective Pharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAG
Infectious Disease & Antimicrobials Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Oral antibiotics
  • Anti-infective therapeutics
  • Penem antibiotics
  • Urinary tract infection treatment
  • Multi-drug resistant pathogens

Where Iterum Therapeutics is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices3 records

Markets served

Iterum Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. ORLYNVAH Product Sales: Iterum generates revenue through direct sales of its FDA-approved antibiotic ORLYNVAH (oral sulopenem) for the treatment of uncomplicated urinary tract infections. The product launched commercially in August 2025 with initial Q3 2025 revenue of $0.4 million. The company projects 2026 net product sales between $5 million and $15 million depending on uptake and payer coverage.

Pricing tiers

ModelBillingPrice
OtherOne timePatient copay program

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Iterum Therapeutics product offering

Product offering

Core offering

Iterum Therapeutics develops and commercializes ORLYNVAH (sulopenem etzadroxil and probenecid), a novel oral penem antibiotic bilayer tablet approved by the FDA for treating uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options. The company also holds patents and development assets around sulopenem, including IV formulations and a susceptibility test disc for laboratory use.

Product overview

Iterum Therapeutics is a clinical-stage pharmaceutical company that received FDA approval for its single commercial product, ORLYNVAH (sulopenem etzadroxil and probenecid), an oral penem antibiotic. The company also developed an IV formulation of sulopenem, though it remains unapproved. Both oral and IV formulations received Qualified Infectious Disease Product (QIDP) and Fast Track designations from the FDA in seven indications. The company commercialized ORLYNVAH through partnerships with EVERSANA for commercialization services, McKesson and Cencora for specialty distribution, and ACS Dobfar for manufacturing. The company filed for winding up in March 2026 and is in the process of dissolution.

Differentiator

Problem solved

Functional benefit

Brands

  • ORLYNVAH: Novel oral penem antibiotic (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs). The first and only oral penem antibiotic approved in the U.S.

Products and services

  • ORLYNVAH (sulopenem etzadroxil and probenecid) Novel oral penem antibiotic combining sulopenem etzadroxil with probenecid in a bilayer tablet, FDA-approved (October 2024) for treating uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options, with potent activity against ESBL- and AmpC-producing Enterobacterales.
  • Sulopenem Antimicrobial Susceptibility Test Disc (2 µg)

Quantifiable outcome

  • 57% of initial uncomplicated UTI infections were resistant to at least one antibiotic class; 13% were resistant to three or more
  • +2 more outcomes

Companies that use Iterum Therapeutics

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Iterum Therapeutics technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature2 records

Iterum Therapeutics partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Teneo Restructuring (Ireland) LimitedcoreOthers · 27 March 2026Appointed as Joint Provisional Liquidators to Iterum Therapeutics plc and Iterum Therapeutics International Limited following High Court order in Ireland. Damien Murran and Jennifer McMahon overseeing company wind-down and dissolution process.
  • ACS Dobfar S.p.AcoreImplementation/ SI/ Consulting Partner · 1 July 2025Commercial Manufacturing and Supply Agreement for the manufacture and supply of ORLYNVAH bilayer tablets for commercial supply purposes.
  • EVERSANA Life Science Services, LLCcoreChannel Partner/ Reseller/ Distributor · 1 June 2025Product Commercialization Agreement for commercialization of ORLYNVAH in the U.S. EVERSANA provides sales and commercial operations services, marketing, logistics, channel management, regulatory, medical affairs and other services related to commercialization of ORLYNVAH in the United States.
  • Pfizer Inc.coreOthersLicensor of sulopenem technology with license agreement requiring royalty payments. In May 2025, Pfizer agreed to extend the deferral term for payment of the $20.0 million regulatory milestone payment until October 25, 2029.
  • McKessonminorChannel Partner/ Reseller/ DistributorSpecialty pharmacy distributor for ORLYNVAH allowing certain physicians to procure the product directly through McKesson specialty distribution channel.
  • Cencora (formerly AmerisourceBergen)minorChannel Partner/ Reseller/ DistributorSpecialty pharmacy distributor for ORLYNVAH allowing certain physicians to procure the product directly through Cencora specialty distribution channel.
  • Top three Medicare Part D Pharmacy Benefit ManagerscoreChannel Partner/ Reseller/ DistributorRebate agreements signed with top three Medicare Part D PBMs providing formulary coverage for ORLYNVAH. Initial agreements covered over 3.5 million lives, expanding to 10+ million lives with Medicare Advantage and Medicare Prescription Drug formularies.

Scale indicators7 records

Recent moves8 records

Expansion highlights5 records

Iterum Therapeutics competitors and assessment

Company assessment

Direct peers

  • Spero Therapeutics: Spero is the closest direct competitor, developing oral antibiotics (including tebipenem HBr) for complicated uUTIs caused by resistant pathogens — the same anti-infective / AMR niche as ORLYNVAH.
  • Melinta Therapeutics: Melinta is a focused anti-infectives company (Baxdela, Orbactiv, Kimyrsa, Minocin) with hospital-channel infrastructure, comparable in size and therapeutic focus to Iterum at the point of ORLYNVAH's launch.
  • Tetraphase Biosciences: Tetraphase developed eravacycline (Xerava) for complicated intra-abdominal infections — a similarly differentiated, smaller-player anti-infective against MDR gram-negatives, now operating under Innoviva.
  • Paratek Pharmaceuticals: Paratek developed and commercialized Nuzyra (omadacycline), a differentiated antibiotic for community-acquired bacterial pneumonia and acute skin infections, mirroring Iterum's small-cap anti-infective commercial model.
  • Nabriva Therapeutics: Nabriva developed and commercialized lefamulin (Xenleta), a first-in-class pleuromutilin antibiotic for community-acquired bacterial pneumonia — a closely analogous small-cap anti-infective launch with similar commercial-execution challenges.

Broad incumbents

  • GSK: GSK received FDA approval for gepotidacin (Blujepa) for uUTIs in 2025, directly competing with ORLYNVAH in the resistant-uUTI space while operating across a much broader infectious disease and vaccines portfolio.
  • Shionogi: Shionogi developed Fetroja/cefiderocol for MDR gram-negative infections, the closest large-pharma analog to sulopenem's spectrum; comparable in mechanism intent (siderophore/β-lactam strategy vs. penem strategy) and resistant-pathogen positioning.
  • Merck & Co. Merck markets Recarbrio and Zerbaxa for MDR gram-negative infections, providing a comparable large-cap commercial benchmark for what scaled uptake of a hospital/community β-lactam-based franchise looks like in the U.S.

Emerging players

  • VenatoRx Pharmaceuticals: VenatoRx is developing cefepime-taniborbactam for MDR gram-negative infections (acquired by GARDP for global rights), directly comparable as a small-cap anti-infective R&D story targeting the same AMR unmet need.

Others

  • Pfizer: Pfizer is the licensor of the sulopenem technology and a broader anti-infective incumbent (with established hospital antibiotics), making it the most operationally entangled peer via the deferred $20M milestone and ongoing royalty relationship.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Iterum Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Iterum Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

Iterum Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Iterum Therapeutics funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Iterum Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Iterum Therapeutics

What does Iterum Therapeutics do?

Iterum Therapeutics develops and commercializes ORLYNVAH (sulopenem etzadroxil and probenecid), a novel oral penem antibiotic bilayer tablet approved by the FDA for treating uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options. The company also holds patents and development assets around sulopenem, including IV formulations and a susceptibility test disc for laboratory use.

Is Iterum Therapeutics a public or private company?

Iterum Therapeutics is a public company. It is classified as public and is currently closed.

When was Iterum Therapeutics founded?

Iterum Therapeutics was founded in 2015. It employs 11 to 50 people.

Where is Iterum Therapeutics based?

Iterum Therapeutics is headquartered in Dublin, Ireland, in the Europe region.

How does Iterum Therapeutics make money?

One revenue line is on record: ORLYNVAH Product Sales.

Who are Iterum Therapeutics's main competitors?

Direct peers on record are Spero Therapeutics, Melinta Therapeutics, Tetraphase Biosciences, Paratek Pharmaceuticals and Nabriva Therapeutics. Broad incumbents are GSK, Shionogi and Merck & Co.. VenatoRx Pharmaceuticals is listed as an emerging player. Pfizer is listed as an others.

Does Iterum Therapeutics have an API?

No public API is recorded for Iterum Therapeutics.

What industry is Iterum Therapeutics in?

Iterum Therapeutics's product category is Anti-Infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsAnalyzing Iterum Therapeutics (NASDAQ:ITRM) and Ensysce Biosciences (NASDAQ:ENSC)Ensysce Biosciences outperforms Iterum Therapeutics on revenue, earnings, and analyst ratings, with a consensus target price of $2.00 implying 378% upside. Iterum Therapeutics beats Ensysce on 8 of 14 factors, but Ensysce is more affordable and less volatile.American Banking and Market NewsContrasting Supernus Pharmaceuticals (NASDAQ:SUPN) & Iterum Therapeutics (NASDAQ:ITRM)Supernus Pharmaceuticals and Iterum Therapeutics are compared on revenue, earnings, valuation, and analyst ratings. Supernus has higher revenue ($718.95M vs $390M) and a lower P/E ratio, with a consensus price target of $63.00 implying 54.79% upside. Iterum's beta is 2.96, indicating higher volatility.American Banking and Market NewsCritical Survey: Iterum Therapeutics (NASDAQ:ITRM) vs. Sol-Gel Technologies (NASDAQ:SLGL)Sol-Gel Technologies beats Iterum Therapeutics on 10 of 15 factors, including higher revenue and a lower price-to-earnings ratio. Analysts rate Sol-Gel more favorably with a consensus target price of $197.50, implying a 207.39% upside. Institutional ownership is higher for Sol-Gel at 26.2% versus 9.2% for Iterum.Markets DailyPfizer (NYSE:PFE) vs. Iterum Therapeutics (NASDAQ:ITRM) Head-To-Head ContrastPfizer and Iterum Therapeutics are compared across earnings, risk, analyst ratings, dividends, institutional ownership, valuation, and profitability. Pfizer has higher revenue and earnings, lower volatility, and stronger institutional ownership, while Iterum is more volatile and unprofitable. Analysts rate Pfizer more favorably with a consensus target price of $28.72.Markets DailyFinancial Review: Arcutis Biotherapeutics (NASDAQ:ARQT) and Iterum Therapeutics (NASDAQ:ITRM)Arcutis Biotherapeutics and Iterum Therapeutics are compared on profitability, ownership, and analyst ratings. Arcutis beats Iterum on 12 of 14 factors, with higher revenue and a stronger consensus rating. Analysts see a 41.44% upside in Arcutis, while Iterum trades at a lower P/E.American Banking and Market NewsComparing Arcutis Biotherapeutics (NASDAQ:ARQT) & Iterum Therapeutics (NASDAQ:ITRM)Arcutis Biotherapeutics and Iterum Therapeutics are compared on risk, valuation, earnings, and analyst ratings. Arcutis has higher revenue, earnings, and a stronger consensus rating, while Iterum is more volatile and less profitable. Analysts favor Arcutis with a 41.38% upside target.Pedaily一批商业化Biotech的消亡The article cites three biotech cases: Iterum Therapeutics applied for liquidation in Ireland in March 2026, Theravance Biopharma shut down its R&D department after Phase III failures, and Karyopharm Therapeutics reported $30.8 million in Xpovio sales with only $65.4 million in cash reserves. The author argues that commercialization amplifies risk rather than eliminating it, and that continuous innovation remains the foundation of biotech survival.School of Public HealthCOMMENTARY: We must address the market challenges behind microbiome-sparing antibioticsThe article argues that despite scientific advances in microbiome-sparing antibiotics, investment remains critically low due to the paradoxical nature of the antibiotic market where stewardship limits commercial returns. It highlights the recent bankruptcy of Iterum Therapeutics as an example of this failure and calls for policy interventions like the PASTEUR Act to create viable market incentives for innovation.GlobeNewswireDelisting of Securities from The Nasdaq Stock MarketNasdaq announced delisting of securities for MingZhu Logistics, Harrison Global, MSP Recovery, EPWK Holdings, Inspire Veterinary, Synlogic, Twin Hospitality, FAT Brands, Carbon Revolution, ScanTech AI, CASI Pharmaceuticals, TIAN RUIXIANG, Oak Woods, Iterum Therapeutics, IO Biotech, and QVC Group. All listed companies had suspended shares since December 2025 to April 2026.ThehillAntibiotic resistance is growing — don’t delay new antibioticsIterum Therapeutics, a small biotech company, received FDA approval for its novel antibiotic Orlynvah in early 2025 but announced plans to wind down operations due to poor sales and high commercialization costs. The company's collapse exemplifies a systemic problem: antibiotic stewardship practices intentionally suppress drug sales to preserve effectiveness, making it economically impossible for developers to recoup development costs or attract investment. With antibiotic-resistant infections contributing to nearly 5 million deaths annually worldwide and drug-resistant bacteria generating over $4.6 billion in annual U.S. healthcare costs, the article argues that passage of market-based incentives like the Pasteur Act is necessary to prevent further collapses of antibiotic developers even after regulatory success.